Advanced in Virilizing Ovarian Tumor

Dr. Mary J. Wilkinson

Oncology | Hematology | Hematology Oncology
Johns Hopkins University
5255 Loughboro Rd Nw, 
Washington, DC 
 (521.3 mi)
Offers Telehealth
Advanced in Virilizing Ovarian Tumor
Johns Hopkins University
5255 Loughboro Rd Nw, 
Washington, DC 
 (521.3 mi)
OverviewInsuranceLocationsClinical Research

Overview

Mary Wilkinson is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Wilkinson and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
Sibley Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

JOHNS HOPKINS UNIVERSITY
5255 Loughboro Rd Nw, Washington, DC 20016
Other Locations
JOHNS HOPKINS UNIVERSITY
8600 Old Georgetown Rd, Bethesda, MD 20814

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Enrollment Status: Completed
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Fostamatinib, Paclitaxel
Study Phase: Phase 1
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim
Study Phase: Phase 2
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
An Exploratory Pilot Study of Vitamin D Supplementation in Women With DCIS and/or LCIS
An Exploratory Pilot Study of Vitamin D Supplementation in Women With DCIS and/or LCIS
Enrollment Status: Terminated
Publish Date: December 16, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
View 11 Less Clinical Trials

8 Total Publications

The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer.
The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: November 02, 2024
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Frederick D. Min
Hematology Oncology | Hematology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Frederick D. Min
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

7350 Van Dusen Rd, Suite 370, 
Laurel, MD 
 (16.1 mi)
301-982-9800
Languages Spoken:
English, Korean
Accepting New Patients
Offers Telehealth

Frederick Min is a Hematologist Oncology specialist and a Hematologist in Laurel, Maryland. Dr. Min and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Pleuropulmonary Blastoma, and Ovarian Cancer. Dr. Min is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Frederick P. Smith
Oncology | Hematology
Distinguished in Virilizing Ovarian Tumor
Dr. Frederick P. Smith
Oncology | Hematology

Rcca MD LLC

5454 Wisconsin Ave, Suite 1300, 
Chevy Chase, MD 
 (2.2 mi)
301-657-4588
Languages Spoken:
English, Burmese
See accepted insurances
Accepting New Patients

Frederick Smith is an Oncologist and a Hematologist in Chevy Chase, Maryland. Dr. Smith and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Ovarian Carcinosarcoma, and Virilizing Ovarian Tumor. Dr. Smith is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Panayotis Ledakis
Hematology Oncology | Oncology | Hematology
Distinguished in Virilizing Ovarian Tumor
Dr. Panayotis Ledakis
Hematology Oncology | Oncology | Hematology

Lutherville Hematology And Oncology Services

7602 Belair Rd, 
Baltimore, MD 
 (43.4 mi)
410-494-9099
Languages Spoken:
English, French, Greek
See accepted insurances
Accepting New Patients
Offers Telehealth

Panayotis Ledakis is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Ledakis and is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Appendix Cancer, Desmoplastic Small Round Cell Tumor, Anemia, Colorectal Cancer, and Ureteroscopy. Dr. Ledakis is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile